8-KEarnings & ResultsExhibits & Filings

THERMO FISHER SCIENTIFIC INC. 8-K Report, Financial Results (Apr 29, 2021)

Filed April 29, 2021For Securities:TMO

Summary

Thermo Fisher Scientific Inc. (TMO) filed an 8-K on April 29, 2021, to report its financial results for the fiscal quarter ended April 3, 2021. The filing includes a press release detailing these results, which is furnished as an exhibit. Investors should note that this information is furnished, not filed, meaning it's not subject to the same liabilities under Section 18 of the Exchange Act, though it may be incorporated by reference in other filings if explicitly stated. The report also contains a cautionary statement regarding forward-looking statements, highlighting potential risks and uncertainties that could affect future performance. Key factors include the ongoing COVID-19 pandemic, product development, economic conditions, international operations, regulatory changes, and the integration of recent or pending acquisitions, notably the acquisition of PPD, Inc. Investors are encouraged to review the company's Form 10-K for a more comprehensive understanding of these risks.

Key Highlights

  • 1Thermo Fisher Scientific announced Q1 2021 financial results via an 8-K filing on April 29, 2021.
  • 2The press release containing the Q1 2021 financial results is attached as Exhibit 99.1.
  • 3Information regarding financial results is furnished, not filed, under Item 2.02.
  • 4The filing includes a cautionary statement about forward-looking statements and associated risks.
  • 5Key risks mentioned include the impact of COVID-19, product innovation, economic conditions, and regulatory changes.
  • 6The pending acquisition of PPD, Inc. is specifically mentioned as a factor influencing expected benefits.
  • 7Investors are directed to the Form 10-K for detailed risk factors.

Frequently Asked Questions

The primary purpose of this 8-K filing is to announce and provide Thermo Fisher Scientific's financial results for the fiscal quarter ended April 3, 2021, as detailed in an accompanying press release.

When information is 'furnished' under Item 2.02, it is generally not subject to the liabilities of Section 18 of the Securities Exchange Act of 1934, which pertains to misleading statements in 'filed' documents. However, it can still be considered by investors and may be incorporated into other SEC filings if the company explicitly states so.

The company highlights several risks including the ongoing COVID-19 pandemic, the need for new product development and adaptation to technological changes, general economic conditions, international operations' exposure to economic and political factors, regulatory changes, and potential challenges in realizing expected benefits from acquisitions, particularly the pending PPD, Inc. acquisition.

The filing directs investors to Thermo Fisher Scientific's Annual Report on Form 10-K for the year ended December 31, 2020, which is filed with the SEC and available in the 'Investors' section of the company's website, for a more comprehensive discussion of risk factors.